IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.81 -	0.07 91.96%	0.93 1,324.37%	3.71 300.98%	0.87 76.65%	0.71 17.82%
company equity multiplier	1.27 -	-3.27 357.45%	1.14 134.95%	1.11 3.11%	1.45 31.43%	1.35 6.99%
days of inventory outstanding
days of payables outstanding						134.85 -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	1.04 -	1 3.70%	1 0%	1 0%	1 0%	0.99 1.09%
effective tax rate	0.03 -	0.01 56.25%			0.04 -	1.09 2,729.72%
enterprise value multiple	-28.79 -	-18.76 34.85%	-20.84 11.11%	-0.66 96.83%	-1.27 91.82%	-0.89 29.60%
fixed asset turnover
free cash flow per share	-0.57 -	-0.55 4.26%	-0.37 32.87%	-1.39 277.55%	-1.33 4.25%	-0.80 39.60%
gross profit margin
interest coverage	-143.14 -				25.86 -
inventory turnover
long term debt to capitalization				0.04 -	0.16 269.17%	0.12 27.58%
net income per ebt	1 -	1 0%	1 0%	1 0%	0.96 3.87%	1 4.02%
net profit margin
operating cash flow per share	-0.45 -	-0.51 14.07%	-0.37 28.26%	-1.36 269.11%	-1.15 15.10%	-0.78 32.06%
operating profit margin
payables turnover						2.71 -
pretax profit margin
price fair value	13.28 -	-271.17 2,141.42%	10.61 103.91%	1.15 89.19%	2.13 85.89%	1.65 22.43%
receivables turnover
return on assets	-0.35 -	-4.54 1,187.03%	-0.41 90.99%	-0.35 15.20%	-0.83 139.13%	-0.89 7.27%
return on capital employed	-0.37 -	-10.63 2,804.52%	-0.47 95.61%	-0.37 21.43%	-1.05 185.82%	-1.07 2.24%
return on equity	-0.45 -	14.84 3,413.45%	-0.47 103.15%	-0.38 17.84%	-1.21 214.30%	-1.20 0.23%
total debt to capitalization			0.01 -	0.06 531.06%	0.21 245.87%	0.16 20.12%

NASDAQ:INAB

IN8bio, Inc.

Last Close

1.02

17/05 20:00

Market Cap

56.27M

Beta: -

Volume Today

37.48K

Avg: 3.83M

PE Ratio

−1.32

PFCF: −1.90